These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Strategizing the clone wars: pharmacological control of cellular sensitivity to radiation. Kimple RJ Mol Interv; 2010 Dec; 10(6):341-53. PubMed ID: 21263160 [TBL] [Abstract][Full Text] [Related]
3. Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Pauwels B; Wouters A; Peeters M; Vermorken JB; Lardon F Future Oncol; 2010 Sep; 6(9):1485-96. PubMed ID: 20919831 [TBL] [Abstract][Full Text] [Related]
4. Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins. Lee TK; Stupans I J Pharm Pharmacol; 2002 Nov; 54(11):1435-45. PubMed ID: 12495545 [TBL] [Abstract][Full Text] [Related]
5. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975 [TBL] [Abstract][Full Text] [Related]
6. New and emerging radiosensitizers and radioprotectors. Spalding AC; Lawrence TS Cancer Invest; 2006; 24(4):444-56. PubMed ID: 16777698 [TBL] [Abstract][Full Text] [Related]
13. Combination of taxanes with radiation: preclinical studies. Milas L; Milas MM; Mason KA Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):12-26. PubMed ID: 10210536 [TBL] [Abstract][Full Text] [Related]
14. New concepts for phase I trials: evaluating new drugs combined with radiation therapy. Deutsch E; Soria JC; Armand JP Nat Clin Pract Oncol; 2005 Sep; 2(9):456-65. PubMed ID: 16264990 [TBL] [Abstract][Full Text] [Related]
15. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798 [TBL] [Abstract][Full Text] [Related]
16. [Biological basis for concomitant chemoradiotherapy in carcinomas]. Favaudon V; Noël G Bull Cancer; 2005 Dec; 92(12):1027-31. PubMed ID: 16396748 [TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model. Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108 [TBL] [Abstract][Full Text] [Related]
18. Targeting base excision repair as a sensitization strategy in radiotherapy. Vens C; Begg AC Semin Radiat Oncol; 2010 Oct; 20(4):241-9. PubMed ID: 20832016 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway. Zhang AL; Russell PJ; Knittel T; Milross C Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933 [TBL] [Abstract][Full Text] [Related]
20. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Goldstein M; Kastan MB Annu Rev Med; 2015; 66():129-43. PubMed ID: 25423595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]